Regulatory Blog

Clinical trials have traditionally been conducted using separate protocols to evaluate individual drugs for specific diseases or patient populations. While this approach has contributed significantly to medical innovation, it can be resource-intensive, time-consuming, and challenging when studying rare diseases or rapidly evolving therapeutic areas. To improve the efficiency of clinical development, the FDA issued the draft guidance "Master Protocols for Drug and Biological P